Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

US patient dies from infection resistant to all antibiotics
drugs
‘Isolates that are resistant to all antimicrobials are very uncommon’.
Klebsiella pneumoniae was resistant to 26 drugs

A US patient has died after contracting an infection that was resistant to all available antibiotics, the Centers for Disease Control and Prevention (CDC) has revealed.

The female patient, who was in her 70s, was a resident of Washoe County in Reno, Nevada, but had recently returned from an extended trip to India.

She was admitted to an acute care hospital in the US in August 2016, with an initial diagnosis of systemic inflammatory response syndrome, most likely from an infected hip seroma, following an earlier right femur fracture and subsequent osteomyelitis of the femur and hip, for which she had been admitted to hospital in India on multiple occasions in the previous two years.

The patient was placed in a single room under contact precautions after testing identified carbapenem-resistant Enterobacteriaceae (CRE) - in this case Klebsiella pneumoniae - which was resistant to all available antimicrobial drugs. The patient went on to develop septic shock and died in September.

CDC confirmed the mechanism of antimicrobial resistance to be New Delhi metallo-beta-lactamase (NDM), an enzyme that makes bacteria resistant to a broad range of beta-lactam antibiotics.

Testing revealed the isolate was resistant to 26 antibiotics, including all aminoglycosides and polymyxins that were tested, and intermediately resistant to tigecycline, which was developed in response to emerging antibiotic resistance.

According to a report on the case by CDC, ‘isolates that are resistant to all antimicrobials are very uncommon’.

Dr David Brown, chief scientist at Antibiotic Research UK, told BBC News: "It is still quite unusual for a bacterial infection to be resistant to such a large number of antibiotics. Fortunately it is an extreme case, but it may soon become all too common."

To slow the spread of bacteria with resistance mechanisms, such as NDM and MCR-1, CDC recommends that when these bacteria are identified, facilities use proper infection control contact precautions, and that health care contacts are evaluated for evidence of transmission.

Health care facilities should also obtain the patient’s history of exposure outside the region upon admission, and consider screening for CRE when patients report recent exposure outside of the US, or in regions of the US known to have higher rates of CRE.

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.